chemistry proceedings

MDPI

Proceeding Paper

Rearrangement of Imidazolidine to Piperazine Rings in the Presence of Dy^{III} †

Julio Corredoira-Vázquez [1,2], Paula Oreiro-Martínez [1], Ana M. García Deibe [1], Jesús Sanmartín-Matalobos [1] and Matilde Fondo [1,*]

[1] Departamento de Química Inorgánica, Facultade de Química, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
[2] Phantom-g, CICECO—Aveiro Institute of Materials, Department of Physics, University of Aveiro, 3810-193 Aveiro, Portugal
* Correspondence: matilde.fondo@usc.es; Tel.: +34-881814231
† Presented at the 26th International Electronic Conference on Synthetic Organic Chemistry, 15–30 November 2022; Available online: https://sciforum.net/event/ecsoc-26.

Abstract: The formation of imidazolidines from secondary amines and aldehydes is well known. This small cycle can act as a nitrogen donor, and it is usually stable when it coordinates to metal ions. Sometimes, imidazolidines acting as ligands undergo breaking of the C-N bond when coordinating to the metal center, yielding related amines. However, the reorganization of the imidazolidine into a piperazine ring is quite an unusual process. In this work, we describe the transformation of a zinc complex with a ligand containing two imidazolidine moieties into a zinc complex with a piperazine fragment as donor, in the presence of a dysprosium salt.

Keywords: imidazolidine; piperazine; dysprosium(III)

Citation: Corredoira-Vázquez, J.; Oreiro-Martínez, P.; Deibe, A.M.G.; Sanmartín-Matalobos, J.; Fondo, M. Rearrangement of Imidazolidine to Piperazine Rings in the Presence of Dy^{III}. *Chem. Proc.* **2022**, *12*, 30. https://doi.org/10.3390/ecsoc-26-13547

Academic Editor: Julio A. Seijas

Published: 14 November 2022

1. Introduction

Nitrogen heterocycles are undoubtedly the most important structural motifs in medical chemistry and pharmaceuticals [1]. These include imidazolidines and piperazines [2], which are also potential ligands for the formation of metal complexes [3,4]. The stability of imidazolidine-based complexes greatly depends on the substituents attached to the nitrogen donors. Thus, there are many complexes with imidazolidine ligands that have been shown to be stable in solution, while others undergo hydrolysis very easily [5]. When this hydrolysis takes place, it typically cleaves the imidazolidine ring to transform the ligand into an amine [5]. However, in some cases, although very rare, the conversion of the imidazolidine ring into a piperazine heterocycle has also been described. To our knowledge, this transformation has only been described twice in the literature, and it took place in the presence of Cu^{II} ions [6,7]. In this work, we describe the conversion of a ligand containing two imidazolidine rings into one with a piperazine cycle, a reaction that occurs in the presence of a dysprosium(III) salt.

2. Materials and Methods

2.1. Materials and General Methods

All chemical reagents and solvents were purchased from commercial sources, and used as received without further purification. ^{1}H NMR spectra of **1** and **2**·1.75H_2O were recorded on a Varian Inova 400 spectrometer, using DMSO-d_6 as solvent.

Single X-ray data for **2**·1.75H_2O were collected at 100 K on a Bruker D8 VENTURE PHOTON III-14 diffractometer, employing graphite-monochromated Mo-kα (λ = 0.71073 Å) radiation. Multi scan absorption corrections were applied using SADABS [8]. The structure

was solved using standard direct methods, employing SHELXT [9], and then refined using the full matrix least-squares techniques on F^2, using SHELXL [10] from the program package SHELX.

2.2. Syntheses

$[Zn_3(L^1)(OAc)_2]$ (**1**): To a solution of pentaethylenehexamine (0.107 g, 0.461 mmol) in absolute ethanol (12 mL), $Zn(OAc)_2{\cdot}2H_2O$ (0.100 g) and an ethanolic (15 mL) solution of 5-bromo-2-hydroxy-3-methoxybenzaldehyde (0.426 g, 1.844 mmol) were added. The mixture was stirred for 6 h at room temperature, and the solid that precipitated was separated through centrifugation, and dried in air. Yield: 0.125 g (19%). ^{1}H NMR (400 MHz, DMSO-d_6, δ in ppm): 2.09 (s, 6H, CH_3-COO^-); 2.11–2.24 (m, 2H), 2.64–3.05 (m, 8H), 3.53–3.58 (m, 4H), 3.80–3.90 (m, 2H), 3.75–3.83 (m, 2H), 4.10–4.35 (m, 2H) (4H1+ 4H2 + 4H3 + 4H18 + 4H19); 3.48 (s, 6H, OCH_3); 3.63 (s, 6H, OCH_3); 3.69 (s, 1H), 3.73 (s, 1H) (H17 + H17'); 6.75 (s, 2H), 6.82-6.98 (m, 6H) (2H6 + 2H8 + 2H11 + 2 H13); 8.34 (s, 2H, 2H4).

$[Zn_2L^2(NO_3)_2]{\cdot}1.75H_2O$ (**2**$\cdot 1.75H_2O$): To an acetonitrile (8 mL)/methanol (4 mL) solution of **1** (0.022 g, 0.016mmol), $Dy(NO_3)_3{\cdot}6H_2O$ (0.011 g, 0.031 mmol) was added, and the resultant solution was stirred for 4 h at room temperature. Slow evaporation of the obtained solution yielded single crystals of $[Zn_2L^2(NO_3)_2]{\cdot}1.75H_2O$, suitable for single X-ray diffraction studies. Yield: 0.010 (66%) ^{1}H NMR (400 MHz, DMSO-d_6, δ in ppm): aliphatic protons: most of them hidden under the DMSO and water peaks; 3.71 (s, 6H, OCH3); 6.96 (s, 2H), 7.07 (s, 2H) (2H9 + 2H11); 8.51 (s, 2H, H7). Crystal data (at 100(2) K): tetragonal, $I4_1/a$, $C_{28}H_{38}Br_2N_8O_{11.75}Zn_2$, MW = 965.22, with a = 24.077(9) Å, b = 24.077(9) Å, c = 11.8202(6) Å, $\alpha = \beta = \gamma = 90^\circ$, V = 6864.0(6) Å^3, Z = 8; R_1 = 0.0514 and wR_2 = 0.1241 (I > 2σI).

3. Results and Discussion

3.1. Synthesis and Spectroscopic Characterization

The trinuclear zinc complex **1** was obtained using a template method, by mixing pentaethylenehexamine and 5-bromo-2-hydroxy-3-methoxybenzaldehyde in the presence of zinc acetate, as summarized in Figure 1.



Figure 1. Reaction scheme for isolation of zinc complexes **1** and **2**, with numbering scheme for ^{1}H NMR. Solvate molecules are omitted for clarity.

The addition of dysprosium(III) nitrate to an acetonitrile/methanol solution of **1** yields the dinuclear zinc complex **2**·1.75H_2O (Figure 1), which contains the new $[L^2]^{2-}$ donor with a piperazine ring. This heterocycle seems to come from the initial imidazolidine rings present in the $[L^1]^{4-}$ ligand in **1**, through a hydrolysis and rearrangement process. This transformation, although uncommon, has been previously described for copper(II) complexes [6,7] but, as far as we know, it has never been reported in the presence of a lanthanoid ion. Both complexes were characterized using ^{1}H NMR spectroscopy. In addition, **2**·1.75H_2O has been unequivocally identified by single X-ray diffraction studies.

The ^{1}H NMR spectrum of **1** shows one singlet at 8.4 ppm (2H), assigned to the imine protons, and one singlet (2H) and one multiplet (6H) between 6.75 and 6.98 ppm, in agreement with the existence of four aromatic rings, which are not all equivalent. This confirms the tetracondensation of the amine and the aldehyde. Furthermore, the presence of two singlets at *ca*. 3.7 ppm points to the existence of two inequivalent imidazoline protons (H17 and H17′ in Figure 1), in agreement with previous results [11], and this reinforces the tetracondensation. In addition, it should be noted that only one set of signals is present in the ^{1}H NMR spectrum of **1**, in agreement with the existence of only one species in solution, and this spectrum does not show any evidence of hydrolysis.

In the case of **2**·1.75H_2O, the ^{1}H NMR spectrum in DMSO-d_6 (Figure 2) clearly shows the existence of two equivalent imine moieties (singlet at 8.5 ppm), and just two equivalent aromatic rings (two singlets at 6.96 and 7.07 ppm), without any other peak in the aromatic region, indicating the high purity of this species.



Figure 2. ^{1}H NMR spectrum for **2**·1.75H_2O in DMSO-d_6.

Thus, the comparison of this spectrum with that of **1** shows the disappearance of four aromatic protons, according to the removal of two aromatic rings in **2**·1.75H_2O with respect to **1**. Unfortunately, most of the aliphatic protons of **2**·1.75H_2O are hidden by the DMSO and water peaks, but, despite this, the ^{1}H NMR spectrum is in complete agreement with the formation of the new piperazine donor.

Accordingly, the ^{1}H NMR studies suggest that both complexes are stable in solution, and, therefore, that the transformation of complex **1** into **2**·1.75H_2O is mediated by the presence of the dysprosium(III) nitrate.

3.2. Single X-ray Diffraction Studies

Single crystals of $[Zn_2L^2(NO_3)_2]\cdot 1.75H_2O$ (**2**·$1.75H_2O$) were obtained as detailed above. An ellipsoid diagram for **2** is shown in Figure 3, and the main distances and angles are recorded in Table 1.



Figure 3. Ellipsoid (50% probability) diagram for $[Zn_2L^2(NO_3)_2]$ in **2**·$1.75H_2O$.

Table 1. Main bond distances (Å) and angles (°) for **2**·$1.75H_2O$.

Zn1—O1	1.971 (4)	Zn1—N1	2.072 (5)
Zn1—O10	2.367 (6)	Zn1—N2	2.155 (5)
Zn1—O11	2.233 (5)	Zn1—N3	2.160 (5)
Zn1···Zn1 $^{\#1}$	5.943 (1)		
O1—Zn1—N2	169.64 (18)	N3—Zn1—O10	143.84 (19)
N1—Zn1—O11	148.21 (18)	O11—Zn1—O10	54.68 (18)

$^{\#1}$ $-x+1, -y, -z-1$.

The unit cell of **2**·$1.75H_2O$ contains neutral dinuclear $[Zn_2L^2(NO_3)_2]$ molecules and water as solvate. $[Zn_2L^2(NO_3)_2]$ has an inversion center, which makes both halves of the molecule equivalent. In this complex, the new dianionic ligand $[L^2]^{2-}$ acts as a dinucleating octadentate donor, providing an N_3O (N_{imine}, N_{amine}, $N_{piperazine}$ and $O_{phenolate}$) environment for each Zn^{II} ion, with the methoxy oxygen atoms remaining uncoordinated. The metal centers reach their coordinative saturation with a nitrate group, linked in a bidentate chelate mode. Accordingly, both Zn^{II} ions are hexacoordinated, with distances and bond angles that agree with a distorted octahedral geometry. It should be emphasized that the distortion of the octahedron is considerable, since an angle close to 55° is observed (Table 1), a value much lower than what would be expected, but that is quite typical for bidentate chelate nitrates [12]. Both zinc ions are bridged through the *NCCN* fragment of the piperazine ring, which adopts a chair conformation, leading to a Zn···Zn intramolecular distance of *ca.* 5.9 Å. The dinuclear $[Zn_2L^2(NO_3)_2]$ units are connected between them through hydrogen bonds, where only the amine nitrogen atoms (N2) and the water solvate are implicated, and the shortest Zn···Zn intermolecular distance in this arrangement is *ca.* 8.09 Å.

4. Conclusions

This work reports the uncommon conversion of an imidazolidine ligand into a piperazine donor in the presence of a dysprosium(III) salt. Accordingly, herein is described the first piperazine heterocycle isolated from an imidazolidine ligand in the presence of a lanthanoid metal ion.

Author Contributions: Conceptualization, M.F. and J.C.-V.; methodology, J.C.-V., P.O.-M. and M.F.; analysis of the data, M.F., J.C.-V., J.S.-M. and A.M.G.D.; writing—original draft preparation, J.C.-V. and M.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Spanish Ministerio de Innovación, Ciencia y Universidades (PGC2018-102052-B-C21).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: J. Corredoira-Vázquez acknowledges Xunta de Galicia for his postdoctoral fellowship (ED481B-2022-068).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. *J. Med. Chem.* **2014**, *57*, 10257–10274. [CrossRef]
2. Sochacka-Ćwikła, A.; Mączyński, M.; Regiec, A. FDA-approved small molecule compounds as drugs for solid cancers from early 2011 to the end of 2021. *Molecules* **2022**, *27*, 2259. [CrossRef] [PubMed]
3. Fondo, M.; Doejo, J.; García-Deibe, A.M.; Sanmartín, J.; Vicente, R.; El-Fallah, M.S.; Amoza, M.; Ruiz, E. Predetermined ferromagnetic coupling via strict control of M-O-M angles. *Inorg. Chem.* **2016**, *55*, 11707–11715. [CrossRef] [PubMed]
4. Kant, R.; Maji, S. Recent advances in the synthesis of piperazine based ligands and metal complexes and their applications. *Dalton Trans.* **2021**, *50*, 785–800. [CrossRef] [PubMed]
5. Cheaib, K.; Herrero, C.; Guillot, R.; Banse, F.; Mahy, J.-P.; Avenier, F. Imidazolidine ring cleavage upon complexation with first-row transition metals. *Eur. J. Inorg. Chem.* **2017**, *2017*, 3884–3891. [CrossRef]
6. Bera, M.; Ribas, J.; Wong, W.T.; Ray, D. A chair-piperazine bridged *N,N*-dimethylformamide coordinated dicopper(II/II) complex obtained via solution transformation of heterocyclic imidazolidine spacer of a new ligand. *Inorg. Chem. Commun.* **2004**, *7*, 1242–1245. [CrossRef]
7. Zeyrek, C.T.; Elmali, A.; Elerman, Y. Super-exchange interaction in a chair-piperazine bridged dicopper(II/II) complex: Synthesis, crystal structure, magnetic properties and molecular orbital calculations. *Z. Naturforsch. B* **2006**, *61*, 237–242. [CrossRef]
8. *SADABS: Area-Detector Absorption Correction*; Siemens Industrial Automation, Inc.: Madison, WI, USA, 1996.
9. Sheldrick, G.M. SHELXT-Integrated Space-Group and Crystal-Structure Determination. *Acta Cryst.* **2015**, *A71*, 3–8. [CrossRef] [PubMed]
10. Sheldrick, G.M. Crystal structure refinement with SHELXL. *Acta Cryst.* **2015**, *C71*, 3–8. [CrossRef]
11. Fondo, M.; Ocampo, N.; García-Deibe, A.M.; Sanmartín, J. Zn_3, Ni_3, and Cu_3 complexes of a novel tricompartmental acyclic ligand. *Inorg. Chem.* **2009**, *48*, 4971–4979. [CrossRef] [PubMed]
12. Fondo, M.; Corredoira-Vázquez, J.; García-Deibe, A.M.; Sanmartín, J.; Herrera, J.M.; Colacio, E. Designing ligands to isolate *ZnLn* and Zn_2Ln complexes: Field-induced single-ion magnet behavior of the *ZnDy*, Zn_2Dy, and Zn_2Er analogues. *Inorg. Chem.* **2017**, *56*, 5646–5656. [CrossRef] [PubMed]